Search Results

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a basis for a regulatory application.

Pixium Vision SA announces the completion of the reverse stock split, as decided by its Board of Directors on July 27, 2023 on the basis of 1 new share with a par value of 1 euro for 50 existing shares with a par value of 0.02 euro, as authorized at the Extraordinary Shareholders’ Meeting under the Second Resolution on March 8, 2023.

BioSig Technologies, Inc., a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.

Rockwell Medical, Inc. announced financial and operational results for the three months and twelve months ended December 31, 2023.

Tiziana Life Sciences Ltd. today announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences (PNAS), that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab.

Boston Scientific Corporation generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period.

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock.

Evelo Biosciences, Inc. (Nasdaq:EVLO) today announced the publication of a peer-reviewed article explaining the scientific basis of the Small Intestinal Axis1 and that it will hold a Science Symposium on Wednesday, November 30th, including discussion of how this science enables the broad inflammation resolving potential of SINTAX medicines.